Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer

J. Yang, R. S. Pradhan, L. S. Rosen, A. M. Graham, K. D. Holen, H. Xiong
  • Journal of Clinical Pharmacy and Therapeutics, July 2014, Wiley
  • DOI: 10.1111/jcpt.12193
The author haven't finished explaining this publicationThe author haven't finished explaining this publication

The following have contributed to this page: Dr Allison M Kitten

In partnership with: